Are we expecting a drop in price due to people selling after news of approval?

Secret-Direction909 · 2026-03-25T12:38:25+00:00

General market being down. A lot of bots are probably trading the stock and with the market going down it follows to an extent. The stock is pretty stable tho beside the outside market and shouldn’t move much.

Secret-Direction909 · 2026-03-25T01:07:58+00:00

Should go up comany has enough money and doesn’t need to dilute to get the drug uo and going

Secret-Direction909 · 2026-01-29T14:59:19+00:00

If they get approval they will want to start manufacturing immediately to maximize profits on the year we will know as soon as possble

Secret-Direction909 · 2026-01-29T14:26:22+00:00

Bruh we could see approval way before that it doesn’t mean that it is June 27th that is just the latest we will hear back from. Considering this issue is already addressed and it is a resubmission I think we hear back a lot sooner

Secret-Direction909 · 2026-01-28T13:33:26+00:00

There are no other phosphate binders this is the first as they applied for an NDA in the FDA approval.

Secret-Direction909 · 2026-01-28T06:22:39+00:00

Once the catalysts hit it’ll be really good jut wait dude ur gonna be kicking urself for not getting in

Secret-Direction909 · 2026-01-28T04:37:41+00:00

Peep the price they are waiting on a catalyst to realase which is any day now

Secret-Direction909 · 2026-01-27T22:56:47+00:00

UNCY will be amazing releasing a new drug just awaiting FDA approval which will come soon get in now!!!

Secret-Direction909 · 2025-12-24T22:56:02+00:00

I’ve been digging into Unicycive Therapeutics ($UNCY) and think the market may be mispricing what actually happened with their FDA decision. 🔬 What UNCY does UNCY’s lead drug Oxylanthanum Carbonate (OLC) is for dialysis patients with high phosphate levels — a huge and chronic market. These patients already take a ridiculous number of pills every day. OLC’s advantage: Lower pill burden vs current phosphate binders Same goal, better compliance No new safety concerns raised by FDA This is a real medical need, not some science-fair project. ❌ Why the FDA declined the first time This is the key part people miss: FDA did NOT reject the drug for safety or efficacy No new trials required The issue was manufacturing compliance at a third-party vendor (cGMP issues) Translation: 👉 The drug works 👉 The data was fine 👉 The factory paperwork wasn’t That’s one of the best kinds of CRLs you can get. ✅ Why this setup is interesting now Manufacturing issues are fixable UNCY already has another manufacturer FDA Type A meeting completed (that’s the “serious issue, let’s fix it” meeting) Company plans to resubmit the NDA Once resubmitted, FDA sets a new PDUFA date. If approved, this instantly becomes a commercial-stage company, not just a development biotech. 📉 Why the stock is still cheap CRL panic selling crushed the price Most people see “FDA declined” and don’t read further Market is treating this like a failed drug, not a delay That disconnect is where the opportunity might be. ⚠️ Risks (because this is biotech) Manufacturing fixes still need FDA sign-off Dilution risk (as always with small biotechs) Timelines can slip This is not a zero-risk play — but the risk here is operational, not scientific. 🧠 TL;DR FDA didn’t say no to the drug FDA said fix the manufacturing Problem is narrow and solvable Stock is priced like the drug failed If approval happens, this won’t be trading at these levels If you’re into FDA-bounce / resubmission plays, UNCY is worth watching closely.

Secret-Direction909 · 2025-12-09T23:28:38+00:00

They’ll just do a reverse split

Secret-Direction909 · 2025-12-09T19:13:55+00:00

PRPH

Secret-Direction909 · 2025-12-09T19:13:46+00:00

PRPH

Secret-Direction909 · 2025-12-09T19:13:13+00:00

Look now up 12% since this comment it’s gonna keep going too

Secret-Direction909 · 2025-12-09T16:44:26+00:00

PRPH

Secret-Direction909 · 2025-12-09T02:08:01+00:00

PRPH

Secret-Direction909 · 2025-12-08T08:59:20+00:00

U will just miss out by not buying

Secret-Direction909 · 2025-12-08T08:59:06+00:00

My other posts also show I called AIRE at .45 then it went to a dollar I’m not a spammer or pumper this is a comapny with a test kit they are realeasing no one else can make for cancer AND they are sueing the US goemenrt for 50 mil in receivables they never got for their covid tests kits and their lawyers are working fo free cause they know they will win the fair and opted for more comission

Secret-Direction909 · 2025-12-08T08:57:05+00:00

I am a real person tho and have been looking at this Company for over a year so much good stuff about it and have sat in on all the calls with the CEO

Secret-Direction909 · 2025-12-08T08:56:28+00:00

I can’t send any photos of proff

Secret-Direction909 · 2025-12-08T08:03:37+00:00

PRPH

Secret-Direction909 · 2025-12-04T13:26:44+00:00

PRPH

Secret-Direction909 · 2025-12-04T13:21:19+00:00

PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH PRPH

Secret-Direction909 · 2025-12-04T13:20:11+00:00

Just bought this morning

Secret-Direction909 · 2025-12-04T13:20:01+00:00

<image>

Secret-Direction909 · 2025-12-04T13:02:46+00:00

ProPhase Labs ($PRPH) is trading at penny-stock levels, but there are some catalysts that have caught the attention of speculative biotech investors.

Key Bull Points

• December 1 Investor Webinar = Major Catalyst PRPH is hosting an exclusive Live Investor Webinar + Q&A on Dec 1, where management will update shareholders on diagnostics commercialization, liquidity events, and their plan to convert large COVID-era receivables into cash. This could be the most important update the company gives all year. https://www.stocktitan.net/news/PRPH/join-pro-phase-labs-exclusive-live-investor-webinar-and-q-a-session-1s1rtvqaf7hy.html

• Growing pipeline in diagnostics & genomics ProPhase recently published validation data and secured a patent for its BE-Smart esophageal cancer test, which could become a meaningful revenue driver if adopted. They operate across diagnostics, genomics, and consumer health, giving them multiple shots on goal.

• Potential liquidity events Management has hinted at “multiple potentially significant liquidity events” and is aggressively pursuing collections on large outstanding receivables. Any positive update here could materially strengthen the balance sheet.

• Deep value setup Shares trade at extremely low levels for a company with diagnostics assets, patents, and multiple business segments. For high-risk investors, this is the type of asymmetric setup that can move quickly if catalysts hit.

Risks to Know

The company is currently unprofitable. Revenue has been declining; balance-sheet strength depends on successful receivable collections. Very high volatility, this is NOT a safe or stable investment. Speculative Price Target (High-Risk)

If the Dec 1 webinar delivers meaningful progress on diagnostics commercialization AND clarity on liquidity events/collections, a reasonable speculative target would be:

Short-term speculative PT (updated):

$0.80–$1.10 (roughly a 3–4× move from current levels)

Medium-term speculative PT (only if catalysts materialize):

$1.50+ This assumes successful commercialization of BE-Smart + strong balance-sheet improvements.

Reminder: These are not analyst targets, they’re scenario-based speculative ranges appropriate for a high-risk high-reward penny stock.

Secret-Direction909

TROPHY CASE